Search

Displaying results 6811 - 6820 of 8412 in total
  1. Drug

    Navamepent

    go.drugbank.com/drugs/DB21096
    Investigational

    Navamepent has a monoisotopic molecular weight of 304.17 Da.

    Categories: P-glycoprotein inhibitors
  2. Drug

    Aderbasib

    go.drugbank.com/drugs/DB21288
    Investigational

    Aderbasib has a monoisotopic molecular weight of 416.21 Da.

  3. Drug

    Acloproxalap

    go.drugbank.com/drugs/DB21553
    Investigational

    Acloproxalap has a monoisotopic molecular weight of 202.11 Da.

  4. Drug

    D-norleucine

    go.drugbank.com/drugs/DB04419
    Experimental

    An unnatural amino acid that is used experimentally to study protein structure and function. It is structurally similar to METHIONINE, however it does not contain SULFUR.

    Synonyms: D-norleucine, D-(−)-norleucine
  5. Drug

    Sphingosine

    go.drugbank.com/drugs/DB03203
    Investigational

    An amino alcohol with a long unsaturated hydrocarbon chain. Sphingosine and its derivative sphinganine are the major bases of the sphingolipids in mammals. (Dorland, 28th ed)

    Categories: P-glycoprotein substrates
  6. Drug

    AGT-182

    go.drugbank.com/drugs/DB17630
    Investigational

    AGT-182 is an investigational enzyme replacement therapy engineered by the fusion of the iduronate-2-sulfatase (IDS) enzyme and a human insulin receptor monoclonal antibody.

  7. Drug

    CD68-ET3-LV

    go.drugbank.com/drugs/DB32864
    Investigational

    CD68-ET3-LV is an autologous gene therapy consisting of CD34+ hematopoietic stem and progenitor cells transduced ex-vivo with the CD68-ET3-LV lentiviral vector.

  8. Drug

    Human umbilical cord blood mononuclear cell-conditioned medium

    go.drugbank.com/drugs/DB15724
    Experimental

    Transplantation with human umbilical cord blood mononuclear cells (HUCBC) has demonstrated promising results in various disease states. While some of the positive results are credited to HUCBCs’ differentiation potential, the growth fact...

  9. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    Atrasentan is a novel, selective endothelin A receptor antagonist (SERA). In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first...

    Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitors
  10. Drug

    Zibrofusidic acid

    go.drugbank.com/drugs/DB20799
    Investigational

    Zibrofusidic acid has a monoisotopic molecular weight of 594.26 Da.